ABL Bio Inks US$1.06 bln Deal with Sanofi for Parkinson’s Disease Treatment

SEOUL, Jan. 12 (Korea Bizwire) — South Korea’s biotech company ABL Bio Inc. said Wednesday it has entered a global license agreement worth US$1.06 billion with pharmaceutical giant Sanofi to develop and commercialize an antibody candidate to treat Parkinson’s disease. ABL301 is a preclinical antibody therapeutic under development as a potential treatment of synucleinopathy, including [...]